SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

18 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

14 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

07 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

11 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2024 00:05:00 By Nasdaq GlobeNewswire

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

12 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

04 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

14 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

01 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 

10 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

06 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

16 May 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 May 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

07 May 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 Mar 2024 16:01:00 By Nasdaq GlobeNewswire